[InQ]

Oprozomib experiences?

by InQ on Wed Dec 10, 2014 6:12 pm

Does anyone have experiences with oprozomib? The doctor is suggesting we go on this because of kidney impairment.

[Dr. Prashant Kapoor]

Re: Oprozomib experiences?

by Dr. Prashant Kapoor on Sat Dec 13, 2014 1:27 am

Oprozomib is an investigational oral drug belonging to the class of agents called proteasome inhibitors, which includes bortezomib (Velcade) and Kyprolis (carfilzomib). It is similar to carfilzomb [Kyprolis], but has the advantage of oral administration.

Oprozomib has been found to have encouraging single agent activity as reported at the ASH annual meeting last week. The common toxicities include diarrhea, nausea and vomiting. The trial is ongoing and the inclusion criteria allow patients with creatinine clearance of 30 ml/min or higher to enter the study. Creatinine clearance is a measure of the kidney function and the threshold appears to be rather liberal in this trial. Therefore, it allows patients with mild-moderate kidney dysfunction to enroll.

Diarrhea or tumor lysis syndrome caused by oprozomib can occasionally cause kidney failure if not promptly tackled. However, proteasome inhibitors in general are effective in patients with kidney problems associated with myeloma. Carfilzomib has been evaluated in patients with kidney failure and the hope is that oprozomib would be effective as well. The results are awaited.